Celyad Oncology SA (NASDAQ: CYAD) Announces Encouraging Phase 1 IMMUNICY-1 Study Results of CYAD-211

July 9, 2021

Celyad Oncology SA (NASDAQ: CYAD) has announced the initial data from its Phase 1 IMMUNICY-1 CYAD-211 study to treat refractory/relapsed multiple myeloma patients. The company presented the data at the 2021 European Haematology Association Virtual Congress.  Celyad releases IMMUNICY-1 study results  Filippo Petti, Ceylad Oncology’s CEO, said, “We believe the initial data presented today are meaningful beyond the demonstrated clinical activity of CYAD-211. This is the first clinical trial evaluating…

Read More >>